Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$30.80M+910.79%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Newcomer
- Sector
- Industrials
- Industry
- Specialty Business Services
- Employees
- 226
- Beta
- 0.87
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.05
Financials
Revenue
$30.80M+910.8%Net Income
$6.74M+1239.8%EBITDA
$10.71M+1480.4%Free Cash Flow
$62.70M+18402.4%EPS (diluted)
$0.11+840.2%Shares Outstanding (diluted)
62.72M+46.0%Operating Expenses
$10.29MCash & Debt
$34.54MReturn of Capital
$0.00Revenue by Segment (annual)
$82.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $82.03M | $7.55M | $0.14 |
| 2024 | $58.38M | $3.82M | $0.07 |
| 2023 | $47.27M | $6.46M | $0.12 |
| 2022 | $38.03M | $1.03M | $0.02 |
| 2021 | $29.46M | $-2.72M | $-0.05 |
| 2020 | $24.12M | $-9.14M | $-0.19 |
| 2019 | $34.67M | $7.45M | $0.16 |
| 2018 | $23.42M | $2.59M | $0.05 |
| 2017 | $15.23M | $1.79M | $0.04 |
| 2016 | $10.42M | $1.40M | $0.03 |
| 2015 | $8.11M | $-2.41M | $-0.06 |
| 2014 | $10.29M | $2.61M | $0.07 |
| 2013 | $6.31M | $611.7K | $0.02 |
| 2012 | $6.70M | $1.82M | $0.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PAYS's reported EPS growth of 8.2% a year over 13 years.
- EPS in 5 years
- $0.21
- Implied price
- $7.61
- Return from $10.07
- -5.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.79 — -62.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 31 | 37 | 43 | 49 |
|---|---|---|---|---|---|
| -1.8% | -20.7% | -17.2% | -14.2% | -11.6% | -9.2% |
| 3.2% | -16.6% | -12.9% | -9.8% | -7.1% | -4.6% |
| 8.2% | -12.6% | -8.7% | -5.4% | -2.6% | 0.0% |
| 13.2% | -8.5% | -4.5% | -1.1% | 1.9% | 4.6% |
| 18.2% | -4.5% | -0.3% | 3.3% | 6.5% | 9.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
40-65.47%Social Signal Score
Mentions (12)
- Newsfool.com·8d ago·Negative
Paysign: 3 Key Takeaways for Long-Term Investors Pharma patient affordability revenue grew 110% year-over-year to $16.6 million. Losing 113 plasma centers reduces fourth-quarter revenue by $1.5 million.
View source ↗ - Newszacks.com·9d ago·Positive
Is Paysign (PAYS) a Solid Growth Stock? 3 Reasons to Think "Yes" Paysign (PAYS) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·9d ago·Positive
All You Need to Know About Paysign (PAYS) Rating Upgrade to Buy Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·9d ago·Neutral
Down 39.2% in 4 Weeks, Here's Why Paysign (PAYS) Looks Ripe for a Turnaround Paysign (PAYS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Paysign, Inc. (PAYS) Q3 2026 Earnings Call Transcript Paysign, Inc. (PAYS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
Paysign Q3 Earnings Call Highlights Paysign NASDAQ: PAYS reported record third-quarter revenue, operating income and adjusted EBITDA as growth in its patient affordability business more than offset slower growth in plasma payment processing.
View source ↗ - Newsgurufocus.com·34d ago·Negative
PaySign Inc (PAYS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 62/100 On October 19, 2026, PaySign Inc (PAYS) shares rose 3.6% to $15.34, continuing a notable upward trend with a 52-week range of $3.08 to $15.80. The stock has sho
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
Paysign to Host Third Quarter 2026 Earnings Call HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss third quarter 2026 earnings at 5:00 p.m. Eastern time on Monday, November 9, 2026. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 W…
View source ↗ - Newsmarketbeat.com·86d ago·Neutral
Paysign Targets $117M Revenue as Patient-Affordability Business Surges Paysign NASDAQ: PAYS operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation.
View source ↗ - Newszacks.com·88d ago·Neutral
Paysign (PAYS) is an Incredible Growth Stock: 3 Reasons Why Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - Newszacks.com·88d ago·Positive
Paysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock? Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·104d ago·Positive
3 Reasons Growth Investors Will Love Paysign (PAYS) Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗
Earnings
Tue, Mar 23(in 4 months)
Consensus estimate $0.07 per share
Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.11 vs $0.09beat
- Wed, Aug 5$0.11 vs $0.06beat
- Tue, May 12$0.09 vs $0.07beat
- Tue, Mar 24$0.02 vs $0.02beat
- Wed, Nov 12$0.04 vs $0.03beat
- Tue, Aug 5$0.02 vs $0.04miss
Estimates and results for PAYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PAYS officers and directors.
- Bought
- —
- Sold
- $9.4m
0 trades
25 trades
- Herman Joan Msold
- Newcomer Marksold
- Herman Joan Msold
- Herman Joan Msold
- Ngo Michael Csold
- Ngo Michael Csold
- Baker Jeffery Bradfordsold
- Newcomer Marksold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PAYS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
